Top

Published in:

01-02-2010 | Topic Paper

Thulium:YAG laser enucleation (VapoEnucleation) of the prostate: safety and durability during intermediate-term follow-up

Authors: Thorsten Bach, Christopher Netsch, Axel Haecker, Maurice-Stephan Michel, Thomas R. W. Herrmann, Andreas J. Gross

Published in: World Journal of Urology | Issue 1/2010

Abstract

Purpose

Thulium:YAG (Tm:YAG) VapoEnucleation has been introduced and relief of obstruction was demonstrated. The aim of this study was to proof durability of the outcomes in patients with an postoperative follow-up >12 month.

Methods

VapoEnucleation was performed using a 70 Watt continuous-wave-laser. After enucleation tissue was morcellated within the bladder. Patients were followed in terms of improvement of uroflow, intra- and postoperative course and for occurring complications.

Results

88 consecutive patients with prostatic enlargement underwent our initial series of VapoEnucleation. Prostatic volume was 61.3 ± 24.0 cc (30–160). OR-time was 72 min ±26.6 (35–144) and laser-time 32.4 ± 10.1 min (16.3–59.3). Applied laser energy was 123.7 ± 40.6 kJ (67.8–240.9). Foley catheter-time was 2.1 ± 1.06 days on average. In 79/88 patients the postoperative period extended 12 month (mean: 16.5 month). 2 patients deceased during the follow-up, 15 patients did not respond. Therefore, 62/77 patients were available for follow-up. Flow-rate and post-voiding residual urine improved significantly [3.5 vs. 23.3 ml/s (p < 0.001); 121.3 vs. 33.4 ml (p < 0.05)]. IPSS decreased from 18.4 to 6.8, QoL dropped from 4.6 to 1.4. Early complications were urinary tract infection (n: 6/6.8%), bleeding (n: 5/5.6%) and immediate re-treatment (n: 2/2.2%), as well as urethral stricture (n: 1/1.6%) during follow-up. Postoperative short-term dysuria was recorded in 27% of the patients.

Conclusion

VapoEnucleation is a safe and effective minimal invasive treatment modality for BPO. The improvement in voiding and bother is durable in patients with a postoperative period extending 12 month.

Elzayat EA, Elhilali MM (2006) Holmium laser enucleation of the prostate (HoLEP): the endourologic alternative to open prostatectomy. Eur Urol 49:87–91CrossRefPubMed

Bach T, Wendt-Nordahl G, Michel MS, Herrmann TRW, Gross AJ (2009) Feasibility and efficacy of Thulium:YAG laser enucleation (VapoEnucleation) of the prostate. World J Urol Jan 28 (Epub ahead of print)

Bach T, Herrmann TR, Ganzer R, Burchardt M, Gross AJ (2007) RevoLix vaporesection of the prostate: initial results of 54 patients with a 1-year follow-up. World J Urol 25:257–262CrossRefPubMed

Gilling P (2008) Holmium laser enucleation of the prostate (HoLEP). BJU Int 101:131–142PubMed

Ruszat R, Wyler S, Forster T, Reich O, Stief CG, Gasser TC, Sulser T, Bachmann A (2007) Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients with ongoing anticoagulation. Eur Urol 51:1031–1041CrossRefPubMed

Elzayat E, HAbib E, Elhilali M (2006) Holium laser enucleation of the prostate in patients on anticoagulant therapy or with bleeding disorders. J Urol 175:1428–1432CrossRefPubMed

Rajbabu K, Chandrasekara SK, Barber NJ, Wlash K, Muir G (2007) Photoselective vaporization of the prostate with the potassium-titanyl-phosphate laser in men with prostates >100 ml. BJU Int 100:593–598CrossRefPubMed

Kuntz RM, Lehrich K, Ahyai SA (2008) Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomized clinical trial. Eur Urol 53:160–168CrossRefPubMed

Pfitzenmaier J, Gilfrich C, Pritsch M, Herrmann D, Buse S, Haferkamp A, Djakovic N, Pahernik S, Hohenfellner M (2008) Vaporization of prostates of > or =80 mL using a potassium-titanyl-phosphate laser: midterm-results and comparison with prostates of <80 mL. BJU Int 102:332–337CrossRef

10.

Gilling PJ, Kennett K, Das AK, Thompson D, Fraundorfer MR (1998) Holmium laser enucleation of prostate (HoLEP) combined with transurethral tissue morcellation: an update on the early clinical experience. J Endourol 12:457–459CrossRefPubMed

11.

Gilling PJ, Aho TF, Framptom CM, King CJ, Fraundorfer MR (2008) Holmium laser enucleation of the prostate: results at 6 years. Eur Urol 53:744–749CrossRefPubMed

12.

Elzayaz EA, Elhilali MM (2006) Laser treatment of symptomatic benign prostatic hyperplasia. World J Urol 24:410–417CrossRef

13.

Seki N, Mocida O, Kinukawa N, Sagiyama K, Nato S (2003) Holmium laser enucleation for prostatic adenoma: Analysis of learning curve over the curse of 70 consecutive cases. J Urol 170:1847–1850CrossRefPubMed

14.

Placer J, Gelabert-Mas A, Vallmanya F, Manresa JM, Menéndez V, Cortadellas R, Arango O (2009) Holmium laser enucleation of prostate: outcome and complications of self-taught learning curve. Urology 73:1042–1049CrossRefPubMed

15.

Vavassori I, Hurle R, Vismara A, Manzetti A, Valenti S (2004) Holmium laser enucleation of the prostate combined with mechanical morcellation: two years of experience with 196 patients. J Endourol 18:109–112CrossRefPubMed

16.

Bach T, Igelmann H, Herrmann TRW, Ganzer R, Gross AJ (2008) Thulium:YAG vaporesection of the prostate: expert versus novice functional outcome. Eur Urol Suppl 7:203 Abstract 532CrossRef

17.

Naspro R, Bachmann A, Gilling P, Kuntz R, Madersbacher S, Montorsi F, Reich O, Stief C, Vavassori I (2009) A review of recent evidence (2006–2008) for 532-nm photoselective laser vaporisation and holmium laser enucleation of the prostate. Eur Urol 55:1345–1357CrossRefPubMed

Title: Thulium:YAG laser enucleation (VapoEnucleation) of the prostate: safety and durability during intermediate-term follow-up
Authors: Thorsten Bach
Christopher Netsch
Axel Haecker
Maurice-Stephan Michel
Thomas R. W. Herrmann
Andreas J. Gross
Publication date: 01-02-2010
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 1/2010
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-009-0461-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Thulium:YAG laser enucleation (VapoEnucleation) of the prostate: safety and durability during intermediate-term follow-up

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2010

New therapies for non-muscle-invasive bladder cancer

Partners agree that the treatment of LUTS reduces patients’ bother and improves their quality of life: prospective 12 years follow-up study

Penile block is associated with less urinary retention than caudal anesthesia in distal hypospadia repair in children

Urinary collecting system invasion reflects adverse long-term outcome and is associated with simultaneous metastatic spread at the time of surgery and with multilocular dissemination during postsurgical follow-up in renal cell cancer

Identification of urine PLK2 as a marker of bladder tumors by proteomic analysis

Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction